Griphon study pulmonary hypertension

Selexipag for the Treatment of Pulmonary Arterial ...

★ ★ ★ ★ ☆

BackgroundIn a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. MethodsIn this event ...

Selexipag for the Treatment of Pulmonary Arterial ...

Selexipag for the Treatment of Pulmonary Arterial Hypertension

★ ★ ☆ ☆ ☆

nary Arterial Hypertension (GRIPHON) study is provided in the Supplementary Appendix, available at NEJM.org. Drs. Simonneau and McLaughlin contrib- ... pulmonary arterial hypertension or pulmonary

Selexipag for the Treatment of Pulmonary Arterial Hypertension

The Griphon Study - American College of Cardiology

★ ★ ☆ ☆ ☆

5/13/2015 · In the GRIPHON study, 80% of the patients were already receiving PAH therapy at baseline, and 33% of the enrolled patients were receiving two PAH therapies at baseline. The ability to enroll large numbers of patients, in this case over 1,000 patients from 181 sites in …

The Griphon Study - American College of Cardiology

Actelion’s GRIPHON Study on PAH Drug Selexipag Yields ...

★ ★ ★ ★ ☆

10/23/2015 · Actelion Ltd. announced that it will give poster presentation of results from the Phase III GRIPHON clinical trial of selexipag (Uptravi ®).The presentation, to be held at the American College of Chest Physicians’ CHEST Congress in Montréal, Canada, will discuss safety and efficacy results of the investigational drug in pulmonary arterial hypertension (PAH) patients.

Actelion’s GRIPHON Study on PAH Drug Selexipag Yields ...

Long-term survival and safety with selexipag in patients ...

★ ★ ★ ☆ ☆

Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis. In the event-driven GRIPHON study, selexipag significantly reduced the risk of a composite primary endpoint event of morbidity/mortality compared with placebo.

Long-term survival and safety with selexipag in patients ...

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension ...

★ ★ ★ ☆ ☆

4/19/2010 · The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in …

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension ...

Selexipag treatment for pulmonary arterial hypertension ...

★ ★ ★ ★ ☆

1/11/2019 · Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. ... Study population. GRIPHON was a global, double‐blind, randomised, placebo‐controlled, event‐driven, ...

Selexipag treatment for pulmonary arterial hypertension ...

Actelion provides update on Phase III GRIPHON study with ...

★ ★ ☆ ☆ ☆

GRIPHON, (Prostacyclin (PGI2) Receptor agonist in pulmonary arterial hypertension) is a multicenter, double-blind, placebo-controlled trial evaluating the long-term efficacy and safety of oral selexipag in patients with pulmonary arterial hypertension. GRIPHON is close to full enrollment with 1'143 patients randomized, of the targeted 1'150 ...

Actelion provides update on Phase III GRIPHON study with ...

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension ...

★ ★ ★ ★ ★

4/19/2010 · Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (GRIPHON) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension ...

EFFECT OF SELEXIPAG ON MORBIDITY/MORTALITY IN …

★ ★ ★ ★ ★

3/17/2015 · The GRIPHON trial evaluated the long-term effect of selexipag on morbidity/mortality (M/M) as well as tolerability and safety in patients with pulmonary arterial hypertension (PAH). Methods: In this multicenter, double-blind, placebo-controlled, phase 3 study PAH patients (18-75 years) were randomized 1:1 to placebo or selexipag.

EFFECT OF SELEXIPAG ON MORBIDITY/MORTALITY IN …

Selexipag meets primary endpoint in pivotal Phase III ...

★ ★ ☆ ☆ ☆

6/15/2014 · ALLSCHWIL, SWITZERLAND - 16 June 2014 - Actelion Ltd (SIX: ATLN) today announced the top-line results of the pivotal Phase III GRIPHON study …

Selexipag meets primary endpoint in pivotal Phase III ...

GRIPHON - Actelion

★ ★ ☆ ☆ ☆

A multicenter, double-blind, placebo-controlled Phase III study assessing the safety and efficacy of selexipag on morbidity and mortality in patients with pulmonary arterial hypertension STUDY TITLE GRIPHON 4 16 Jun 2014 Investor Webcast - GRIPHON Results * Selexipag is an investigational drug and not approved for use.

GRIPHON - Actelion

Risk assessment in pulmonary arterial hypertension (PAH ...

★ ★ ☆ ☆ ☆

Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study | 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗣𝗗𝗙 on ResearchGate | On Sep 15, 2018, Olivier Sitbon and others ...

Risk assessment in pulmonary arterial hypertension (PAH ...

The TRITON Study is Up and Enrolling for Pulmonary ...

★ ★ ★ ★ ★

9/1/2016 · What is Pulmonary Hypertension? What is Pulmonary Hypertension? ... The TRITON Study is Up and Enrolling for PAH. ... However, we have some recent data from the GRIPHON Study that suggest that adding a third agent may improve outcomes further. However, the GRIPHON Study added Uptravi to patients already being treated with one or two medications

The TRITON Study is Up and Enrolling for Pulmonary ...

Pulmonary Arterial Hypertension-Related Morbidity Is ...

★ ★ ★ ★ ★

2/20/2018 · Patient dispositions from (A) SERAPHIN (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension) and (B) GRIPHON (Selexipag [ACT-293987] in Pulmonary Arterial Hypertension) studies for the months 3, 6 and 12 landmark analyses. *Patients who died or were censored before the time ...

Pulmonary Arterial Hypertension-Related Morbidity Is ...

Macitentan in pulmonary arterial hypertension: The ...

★ ★ ★ ★ ★

6/18/2014 · Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with …

Macitentan in pulmonary arterial hypertension: The ...

Effect of Selexipag on Morbidity/Mortality in Pulmonary ...

★ ★ ★ ★ ★

Request PDF on ResearchGate | On Mar 1, 2015, Vallerie V. McLaughlin and others published Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study

Effect of Selexipag on Morbidity/Mortality in Pulmonary ...

Association of NT-proBNP and Long-Term Outcome in Patients ...

★ ★ ★ ★ ★

Background: N-terminal pro brain natriuretic peptide (NT-proBNP) levels are included in the multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH guidelines. However, data supporting use of NT-proBNP risk thresholds in assessing prognosis in PAH are limited. The GRIPHON trial provides an opportunity to assess the prognostic value of NT-proBNP ...

Association of NT-proBNP and Long-Term Outcome in Patients ...

Association of NT-proBNP and Long-Term Outcome in Patients ...

★ ★ ★ ☆ ☆

Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study Running Title: Chin et al.; ... In the phase III GRIPHON study, the largest PAH randomized controlled trial (RCT) to date, selexipag reduced the risk of the primary composite outcome of morbidity/mortality by 40% .

Association of NT-proBNP and Long-Term Outcome in Patients ...

PAH Study: Is Morbidity Related to Mortality? - Pulmonary ...

★ ★ ★ ★ ☆

Two recent clinical trials related to World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH) – the SERAPHIN and GRIPHON trials – included an assessment of adverse events, such as worsening disease and hospitalization.

PAH Study: Is Morbidity Related to Mortality? - Pulmonary ...

Selexipag may decrease mortality related to pulmonary ...

★ ★ ★ ★ ☆

1. The composite of death from all causes or a complication related to pulmonary arterial hypertension (PAH) was significantly lower in the selexipag group than in the placebo group. 2. Death due to PAH or hospitalization for worsening of PAH was significantly lower in the selexipag group than in ...

Selexipag may decrease mortality related to pulmonary ...
Dovey-coe-novel-study.html,Dowdstown-house-study.html,Dr-donald-tashkin-cannabis-study.html,Draadloos-alarmsysteem-praxis-study.html,Dream-study-and-diabetes.html